-
29: Another Recall for Glenmark: Millions of Bottles of Generic ADHD Drug Pulled
- 2025/03/17
- 再生時間: 5 分
- ポッドキャスト
-
サマリー
あらすじ・解説
Glenmark Pharmaceuticals has recalled nearly 1.5 million bottles of generic atomoxetine (ADHD medication) due to unacceptable levels of a potential carcinogen, N-nitroso atomoxetine. This recall, from January 2024, adds to a series of recent recalls by Glenmark, including potassium chloride capsules (June 2024), diltiazem hydrochloride (December 2024), and various other drugs in 2023 and 2022, due to manufacturing and impurity issues. These repeated recalls raise concerns about Glenmark's quality control, and patients taking Glenmark's atomoxetine are advised to consult their healthcare providers.
Hosted on Acast. See acast.com/privacy for more information.